NasdaqGM:QTRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Quanterix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QTRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.5%

QTRX

1.0%

US Life Sciences

2.9%

US Market


1 Year Return

-10.6%

QTRX

19.6%

US Life Sciences

8.9%

US Market

Return vs Industry: QTRX underperformed the US Life Sciences industry which returned 19.6% over the past year.

Return vs Market: QTRX underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

QTRXIndustryMarket
7 Day-4.5%1.0%2.9%
30 Day-7.6%9.3%10.6%
90 Day23.9%16.0%5.1%
1 Year-10.6%-10.6%19.9%19.6%11.4%8.9%
3 Yearn/a83.9%82.5%34.3%25.4%
5 Yearn/a130.4%127.5%60.7%42.7%

Price Volatility Vs. Market

How volatile is Quanterix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quanterix undervalued compared to its fair value and its price relative to the market?

6.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QTRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QTRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QTRX is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: QTRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QTRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QTRX is overvalued based on its PB Ratio (6.3x) compared to the US Life Sciences industry average (5.9x).


Next Steps

Future Growth

How is Quanterix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QTRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QTRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QTRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QTRX's revenue (22.5% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: QTRX's revenue (22.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QTRX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Quanterix performed over the past 5 years?

-13.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QTRX is currently unprofitable.

Growing Profit Margin: QTRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QTRX is unprofitable, and losses have increased over the past 5 years at a rate of -13.3% per year.

Accelerating Growth: Unable to compare QTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QTRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.6%).


Return on Equity

High ROE: QTRX has a negative Return on Equity (-36.12%), as it is currently unprofitable.


Next Steps

Financial Health

How is Quanterix's financial position?


Financial Position Analysis

Short Term Liabilities: QTRX's short term assets ($122.5M) exceed its short term liabilities ($18.0M).

Long Term Liabilities: QTRX's short term assets ($122.5M) exceed its long term liabilities ($33.2M).


Debt to Equity History and Analysis

Debt Level: QTRX's debt to equity ratio (6.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if QTRX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QTRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: QTRX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.9% each year


Next Steps

Dividend

What is Quanterix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QTRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QTRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QTRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QTRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

E. Hrusovsky (57yo)

5.42yrs

Tenure

US$3,630,996

Compensation

Mr. E. Kevin Hrusovsky has been Chairman at Quanterix Corporation since June 10, 2014 and has been its Chief Executive Officer & President since January 1, 2015. Mr. Hrusovsky served as a Senior Vice Presi ...


CEO Compensation Analysis

Compensation vs Market: E.'s total compensation ($USD3.63M) is about average for companies of similar size in the US market ($USD3.11M).

Compensation vs Earnings: E.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
E. Hrusovsky
Chairman5.42yrsUS$3.63m3.18% $23.8m
David Walt
Co-Founderno dataUS$133.50k5.21% $38.9m
Amol Chaubal
Chief Financial Officer1.17yrsUS$1.44mno data
John Fry
General Counsel & Corporate Secretary0.83yrUS$1.84mno data
Bruce Bal
VP of Operations4.08yrsUS$417.28kno data
David Duffy
Senior VP of Research & Development and CTO7.25yrsUS$511.93k0.13% $1.0m
David Panzerella
Vice President of Sales2.83yrsno datano data
Mark Roskey
Senior Vice President of Commercial & Accelerator5.75yrsUS$319.70kno data
Dawn Mattoon
Senior Vice President of Research Products2.33yrsUS$1.34m0.028% $206.1k
Mary Cortizas
VP of Laboratory Services & CRO0.42yrno datano data

3.5yrs

Average Tenure

57.5yo

Average Age

Experienced Management: QTRX's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
E. Hrusovsky
Chairman5.42yrsUS$3.63m3.18% $23.8m
David Walt
Co-Founderno dataUS$133.50k5.21% $38.9m
Keith Crandell
Independent Director13yrsUS$139.48k0.025% $185.6k
Paul Meister
Independent Director6.75yrsUS$147.46k0.026% $196.8k
Marijn Dekkers
Independent Director3.25yrsUS$136.09k0.016% $119.7k
John Connolly
Independent Director7.5yrsUS$140.00k0.026% $190.8k
Martin Madaus
Lead Independent Directorno dataUS$161.73k0.61% $4.6m
Robert Corn
Member of Scientific Advisory Board11.58yrsno datano data
J. Ramsey
Member of Scientific Advisory Boardno datano datano data
Larry Kricka
Member of Scientific Advisory Boardno datano datano data

7.1yrs

Average Tenure

61yo

Average Age

Experienced Board: QTRX's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QTRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.


Top Shareholders

Company Information

Quanterix Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quanterix Corporation
  • Ticker: QTRX
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$746.278m
  • Shares outstanding: 28.31m
  • Website: https://www.quanterix.com

Number of Employees


Location

  • Quanterix Corporation
  • Building 1
  • 900 Middlesex Turnpike
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QTRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2017

Biography

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 07:31
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.